BNP Paribas Financial Markets’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $37K | Sell |
26,433
-1
| -0% | -$2 | ﹤0.01% | 5028 |
|
|
2026
Q1 | $44.7K | Buy |
26,434
+1,238
| +5% | +$2.2K | ﹤0.01% | 4753 |
|
|
2025
Q4 | $35.8K | Sell |
25,196
-1,424
| -5% | -$2.08K | ﹤0.01% | 4827 |
|
|
2025
Q3 | $43.7K | Buy |
26,620
+13,832
| +108% | +$15.4K | ﹤0.01% | 4654 |
|
|
2025
Q2 | $9.35K | Sell |
12,788
-27,372
| -68% | -$23.6K | ﹤0.01% | 4858 |
|
|
2025
Q1 | $32.4K | Buy |
40,160
+23,536
| +142% | +$27.1K | ﹤0.01% | 4418 |
|
|
2024
Q4 | $22.9K | Sell |
16,624
-245,118
| -94% | -$275K | ﹤0.01% | 4696 |
|
|
2024
Q3 | $272K | Sell |
261,742
-149,358
| -36% | -$205K | ﹤0.01% | 3125 |
|
|
2024
Q2 | $711K | Buy |
411,100
+64,943
| +19% | +$131K | ﹤0.01% | 2475 |
|
|
2024
Q1 | $827K | Buy |
346,157
+302,570
| +694% | +$745K | ﹤0.01% | 2597 |
|
|
2023
Q4 | $145K | Sell |
43,587
-627,576
| -94% | -$1.68M | ﹤0.01% | 3310 |
|
|
2023
Q3 | $2.51M | Buy |
671,163
+632,324
| +1,628% | +$2.92M | ﹤0.01% | 1730 |
|
|
2023
Q2 | $166K | Sell |
38,839
-335,654
| -90% | -$1.98M | ﹤0.01% | 3083 |
|
|
2023
Q1 | $2.56M | Buy |
374,493
+57,566
| +18% | +$447K | ﹤0.01% | 1657 |
|
|
2022
Q4 | $2.51M | Buy |
316,927
+5,634
| +2% | +$43.4K | ﹤0.01% | 1641 |
|
|
2022
Q3 | $2.99M | Buy |
311,293
+291,986
| +1,512% | +$2.95M | ﹤0.01% | 1664 |
|
|
2022
Q2 | $140K | Buy |
19,307
+3,474
| +22% | +$30.2K | ﹤0.01% | 3233 |
|
|
2022
Q1 | $204K | Sell |
15,833
-13,315
| -46% | -$169K | ﹤0.01% | 3130 |
|
|
2021
Q4 | $465K | Sell |
29,148
-32,031
| -52% | -$560K | ﹤0.01% | 3039 |
|
|
2021
Q3 | $983K | Buy |
61,179
+37,421
| +158% | +$549K | ﹤0.01% | 2382 |
|
|
2021
Q2 | $329K | Buy |
23,758
+12,214
| +106% | +$173K | ﹤0.01% | 2718 |
|
|
2021
Q1 | $169K | Buy |
11,544
+3,114
| +37% | +$52.9K | ﹤0.01% | 3117 |
|
|
2020
Q4 | $147K | Sell |
8,430
-6,351
| -43% | -$113K | ﹤0.01% | 3025 |
|
|
2020
Q3 | $271K | Buy |
14,781
+3,015
| +26% | +$56.1K | ﹤0.01% | 2582 |
|
|
2020
Q2 | $210K | Sell |
11,766
-28,736
| -71% | -$486K | ﹤0.01% | 2463 |
|
|
2020
Q1 | $657K | Buy |
40,502
+33,207
| +455% | +$614K | ﹤0.01% | 2198 |
|
|
2019
Q4 | $131K | Sell |
7,295
-2,309
| -24% | -$42.6K | ﹤0.01% | 3160 |
|
|
2019
Q3 | $195K | Buy |
9,604
+3,810
| +66% | +$76.1K | ﹤0.01% | 2764 |
|
|
2019
Q2 | $128K | Sell |
5,794
-5,003
| -46% | -$86.9K | ﹤0.01% | 2882 |
|
|
2019
Q1 | $147K | Buy |
10,797
+10,787
| +107,870% | +$144K | ﹤0.01% | 2880 |
|
|
2018
Q4 | $90 | Sell |
10
-1,411
| -99% | -$16.3K | ﹤0.01% | 4196 |
|
|
2018
Q3 | $23.4K | Hold |
1,421
| – | – | ﹤0.01% | 3346 |
|
|
2018
Q2 | $19.9K | Sell |
1,421
-7,234
| -84% | -$104K | ﹤0.01% | 3500 |
|
|
2018
Q1 | $95.6K | Buy |
8,655
+719
| +9% | +$7.87K | ﹤0.01% | 3204 |
|
|
2017
Q4 | $69.8K | Buy |
7,936
+4,247
| +115% | +$45.5K | ﹤0.01% | 3488 |
|
|
2017
Q3 | $49.2K | Sell |
3,689
-254
| -6% | -$3.36K | ﹤0.01% | 3158 |
|
|
2017
Q2 | $56.6K | Buy |
3,943
+3,837
| +3,620% | +$73.8K | ﹤0.01% | 3127 |
|
|
2017
Q1 | $2.24K | Sell |
106
-349
| -77% | -$8.59K | ﹤0.01% | 3512 |
|
|
2016
Q4 | $12.8K | Sell |
455
-1,560
| -77% | -$43.7K | ﹤0.01% | 3350 |
|
|
2016
Q3 | $54K | Buy |
2,015
+871
| +76% | +$23.8K | ﹤0.01% | 2401 |
|
|
2016
Q2 | $19.3K | Buy |
+1,144
| New | +$21.5K | ﹤0.01% | 2601 |
|
|
2016
Q1 | – | Sell |
-4,580
| Closed | -$105K | – | 2734 |
|
|
2015
Q4 | $105K | Sell |
4,580
-296
| -6% | -$7.62K | ﹤0.01% | 2301 |
|
|
2015
Q3 | $97.7K | Buy |
4,876
+2,914
| +149% | +$88.7K | ﹤0.01% | 2409 |
|
|
2015
Q2 | $56.7K | Buy |
1,962
+1,811
| +1,199% | +$45.8K | ﹤0.01% | 2421 |
|
|
2015
Q1 | $4.62K | Buy |
+151
| New | +$3.9K | ﹤0.01% | 3203 |
|
Other funds holding CHRS
TGY2IT
KKRC
CM
CWG
BNP Paribas Financial Markets's CHRS Position: Q2 2026 in Review
BNP Paribas Financial Markets reduced its Coherus Oncology (CHRS) stake by 0% in Q2 2026, selling an estimated $2 and leaving 26,433 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #5028.
BNP Paribas Financial Markets first reported a position in CHRS in Q1 2015 and has held it in 45 quarters since. The position peaked at $2.99M in Q3 2022. 135 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.
- BNP Paribas Financial Markets held 26,433 shares of Coherus Oncology worth $37K as of Q2 2026.
- BNP Paribas Financial Markets sold 1 Coherus Oncology share in Q2 2026, an estimated $2.
- Coherus Oncology made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5028 holding.
- BNP Paribas Financial Markets first reported a position in Coherus Oncology in Q1 2015 and has held it in 45 quarters since.
- BNP Paribas Financial Markets's Coherus Oncology position peaked at $2.99M in Q3 2022.
- 135 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.